Lantheus Holding Stock Price, News & Analysis

Lantheus Holdings, Inc. (NASDAQ: LNTH) and POINT Biopharma Global, Inc. (NASDAQ: PNT) announced that the FDA has granted Fast Track designation for ¹⁷⁷Lu-PNT2002, a radiopharmaceutical therapy for metastatic castration resistant prostate cancer (mCRPC). This designation accelerates the drug's development and review process to address unmet medical needs in this serious condition. The innovative therapy combines a PSMA-targeted ligand with the radioisotope ¹⁷⁷Lu. The Phase 3 SPLASH trial is complete, with top-line data expected in the latter half of 2023. Enrollment included patients resistant to standard hormonal therapies who are ineligible for chemotherapy, with follow-up extending up to five years.

Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast scheduled for May 4, 2023, at 8:00 a.m. ET to discuss its Q1 2023 financial and operating results. Participants can register online to access the call and are advised to register 15 minutes early to avoid delays. A replay will be available two hours post-webcast, archived for at least 30 days. With over 65 years in the field, Lantheus focuses on enhancing patient outcomes through diagnostics, radiotherapeutics, and AI solutions aimed at disease management. Headquartered in Massachusetts, the company also operates in New Jersey, Canada, and Sweden.

Lantheus Holdings (NASDAQ: LNTH) announced the promotions of Paul Blanchfield to President and Dan Niedzwiecki to Chief Administrative Officer on March 17, 2023. Blanchfield, who previously served as Chief Operating Officer, will oversee commercial and technical operations as well as the medical function. His experience includes significant roles in pharmaceutical management. Niedzwiecki, with over 20 years in legal and business experience, will continue overseeing legal and intellectual property, while also managing human resources and corporate communications. These promotions are expected to support Lantheus’s mission to improve patient outcomes through advanced diagnostics and therapeutic solutions.

Lantheus Holdings, Inc. (NASDAQ: LNTH) reported impressive financial results for 2022, showing a remarkable increase in worldwide revenue of $263.2 million for Q4 and $935.1 million for the full year, which represents growth of 103.1% and 119.9% year-over-year, respectively. The company reported a GAAP net loss of $119.2 million for Q4 but achieved a net income of $28.1 million for the full year. Adjusted fully diluted EPS rose significantly to $1.37 for Q4 and $4.22 for the full year, compared to $0.25 and $0.49 in 2021. Free cash flow also saw substantial growth, standing at $100.6 million for Q4 and $263.4 million for the full year 2022. The company provided a positive outlook for 2023, targeting revenue between $1.140 billion and $1.160 billion.

Lantheus Holdings (NASDAQ: LNTH) presented significant findings on piflufolastat F 18 at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. This PSMA-targeted radiopharmaceutical is approved for imaging in prostate cancer patients. Notably, in a study, management plans were altered in 39.1% of patients with PSA levels below 0.5 ng/mL, with 74.1% of these cases leading to intensified treatment. The findings underscore the importance of piflufolastat F 18 in tailoring patient management strategies for low PSA levels, potentially improving outcomes for those diagnosed with prostate cancer.